Assessment of the Effect of Treatment on the Quality of Life of Adult Keloid
DOI:
https://doi.org/10.60787/tnhj.v22i4.593Keywords:
Keloid, treatment, quality of life, dermatology quality of life index, intralesionalAbstract
Background: Documentations of the effect of treatment on the quality of life of keloid patients are few. This study assessed improvement in quality-of-life following keloid treatment. In addition, to assess which of the offered four modalities of treatment improved quality of life more.
Methods: This quasi-experimental study was conducted on 32 adults who had treatment for keloid disease in the clinic from February 2019 to January 2020. This was part of a comparative study of four different modalities of keloid treatment. The quality of life was assessed before and after treatment using the Dermatology Life Quality Index questionnaire (DLQI). Data was analyzed using SPSS version 23.0
Results: Quality of life significantly improved after treatment with the mean ± SD DLQI score improving from 7.75 ± 6.15 to 4.16 ± 4.93, p=0.001. Quality of life before treatment was impaired in 93.7% and improved to 65.6%. Before treatment, 2 patients had no QOL impairment but this improved to 11 patients after treatment. Prior to treatment, severely impaired QOL was in recorded 28.1% of the patient’s and in 9.4% after treatment. Quality of life improved more in patients who had the combined intralesional triamcinolone acetonide and 5-flourouracil treatment. Significant improvement in the DLQI items of symptomatology, embarrassment, social activity and choice of clothing was noted.
Conclusion: Treatment of keloid improves quality of life and this is dependent on the modality of treatment. The items of quality of life improved include; embarrassment, choice of clothing, interference with social activities, symptoms of pain and pruritus.
Downloads
References
Ud-Din S, BayatA. Strategic Management of Keloid Disease in Ethnic Skin: a Structured Approach Supported by the Emerging literature. Brit. J. Dermatol. 2013;169 s3:71–81.
Akinboro AO, Mejiuni AD, Akinlade MO, Audu BM, Ayodele OE. Spectrum of Skin Diseases Presented at LAUTECH Teaching Hospital, Osogbo, Southwest Nigeria. Int. J. Dermatol. 2015;54: 443–450.
Henshaw EB, Olasode OA. Skin Diseases in Nigeria: TheCalabar Experience. Int. J. Dermatol. 2015; 54:319–326.
Dlova NC, Mankahla A, Madala N, Grobler A, Tsoka-GwegweniJ, Hift RJ. The Spectrum of Skin Diseases in a Black Population in Durban, KwaZulu-Natal, South Africa Int. J. Dermatol. 2015; 54:279–285.
Reinholz M,Poetschke J,Schwaiger H,Epple A,Ruzicka T,Gauglitz GG. The DermatologyLifeQualityIndex as a Means to AssessLifeQualityin Patients with Different Scar Types. J Eur Acad Dermatol Venereol.2015;29:2112-9.
Olaitan P B. Keloids: Assessment of Effects and Psychosocial-impacts on Subjects in a Black African population. Indian J Dermatol Venereol Leprol 2009; 75:368-72.
Lu W, Chu H, Zheng X. Effects on Quality of Life and Psychosocial Wellbeing in Chinese Patients with Keloids. Am J Transl Res. 2021;13:1636-1642
Morales-Sanchez MA, Flores-Ruvalcaba CN, Peralta-Pedrero ML, Villafranca-Dugelby A, Jurado-Santa CruzF. Quality of Life in Adults with Keloid Scars. Cirugía y Cirujanos (English Edition)2019; 86:281-286
Balci DD,Inandi T,Dogramaci CA,Celik E. DLQI Scores in Patients with Keloids and Hypertrophic Scars: a Prospective Case Control Study. J Dtsch Dermatol Ges.2009;7:688-692.
Bijlard E, Kouwenberg CAE, Timman R, Hovius SER, Busschbach JJV, Mureau MAM. Burden of Keloid Disease: A Cross-sectional Health-related Quality of Life Assessment. Acta Derm Venereol 2017; 97: 225–229.
Kassi K, Kouame K, Kouassi A, Allou A, Kouassi I, Kourouma S, Ecra E, Sangare A. Quality of life in black African patients with keloid scars. Dermatol Reports.2020;12: 28-31
Furtado F, Hochman B, Ferrara SF, Dini GM, Camelo-Nunes J, Juliano Y, Ferreira LM. What Factors Affect the Quality of Life of Patients with Keloids? Rev Assoc Med Bras 2009; 55: 700-704.
Walliczek U,Engel S,Weiss C,Aderhold C,Lippert C,Wenzel A,Hörmann K,Schultz JD. Clinical Outcome andQuality of Lifeafter a Multimodal Therapy Approach to Ear Keloids. JAMA Facial Plast Surg.2015;17:333-9.
Poetschke J,Reinholz M,Schwaiger H,Epple A,Gauglitz GG. DLQI and POSAS Scores inKeloidPatients. Facial PlastSurg.2016; 32:289-95
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) –A Simple Practical Measure for Routine Clinical Use. Clinical And Experimental Dermatol. 1994; 19:210-216.
Bischof M, Krempien R, Debus J,Treiber M. Postoperative Electron Beam Radiotherapy for Keloids: Objective Findings and Patient Satisfaction in Self-assessment. Int. J. Dermatol. 2007; 46:971–975.
Bouzari N, Davis SC, Nouri K. Laser Treatment of Keloids and Hypertrophic Scars. Int. J. Dermatol. 2007; 46:80–88.
Abdel-Meguid AM, Weshahy AH, Sayed DS, Refaiy AEM, Awad SMI. Intralesional vs. Contact Cryosurgery in Treatment of Keloids: aClinical and Immunohistochemical Study. Int. J. Dermatol. 2015; 54:468–475
Bijlard E, Timman R, Verduijn GM, Niessen FB, van Neck JW, Busschbach JJV, Mureau MAM. Intralesional Cryotherapy Versus Excision and Corticosteroids or Brachytherapy for keloid Treatment: Study Protocol for a Randomised Controlled trial. Trials 2013, 14:439.
Lee HJ, Jang YJ. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids. Int. J. Mol. Sci. 2018;19(3):711-30.
Coppola MM, Salzillo R, Segreto F, Persichetti P. Triamcinolone Acetonide Intralesional Injection for the Treatment of Keloid Scars: Patient Selection and Perspectives. Clin. Cosm & Invest. Dermatol. 2018; 11:387–396.
Srivastava S, Patil A, Prakash C, Kumari H. Comparison of Intralesional Triamcinolone Acetonide, 5-Fluorouracil, and their Combination in Treatment of Keloids. World J Plast Surg 2018; 7:212-219.
Bijlard E, Steltenpool S, Niessen FB. Intralesional 5-Fluorouracil in Keloid Treatment: A Systematic Review Acta Derm Venereol 2015; 95:778–782.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Journal and Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
